Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice

Irene González-Domínguez, a Jose Luis Martínez, a Stefan Slamanig, a Nicholas Lemus, a Yonghong Liu, a Tsoi Ying Lai, a Juan Manuel Carreño, a Gagandeep Singh, a Gagandeep Singh, a, b Michael Schotsaert, a, b Ignacio Mena, a, b Stephen McCroskery, a Lynda Coughlan, c, d Florian Krammer, e, f Adolfo García-Sastre, a, b, e, f, g Peter Palese, a, f Weina Sun a

a Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
b Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
c Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, Maryland, USA
d Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA
e Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
f Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Irene González-Domínguez and Jose Luis Martínez contributed equally to this article. Author order was determined alphabetically.

ABSTRACT Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion-stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma, and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent, and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant.

IMPORTANCE This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants. Importantly, we show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future.

KEYWORDS cross-protection, pandemic preparedness, neutralizing antibodies, low-cost vaccine platform, multivalent vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19). Since the beginning of the pandemic, the emergence of new variants of concern (VOC) has threatened the protection conferred by vaccines based on the original strain (Fig. 1) (1). In December 2020, the Alpha variant (B.1.1.7) and Beta variant (B.1.351) were declared VOC and spread over the world, followed by the Gamma strain (P.1) that was declared a VOC in January 2021. Both Beta and Gamma variants
exhibited notable resistance to neutralizing antibodies raised against the original strain in humans (1, 2). In May 2021, a strong pandemic wave in India gave rise to a new VOC: the Delta variant (B.1.617.2). This new VOC harbored different mutations in the spike that significantly reduced its sensitivity to neutralizing antibodies, and increased transmissibility, quickly replacing the previous variants worldwide (Fig. 1B) (1, 3). In November 2021, a new VOC named Omicron appeared in South Africa. Since then, Omicron has taken over worldwide, replacing the Delta variant (4). Compared to the previous VOC, Omicron presents the highest number of mutations in the spike protein and has shown the highest drop-in neutralization activity (5, 6). Currently, the Omicron sublineages seems to show even more immune evasion and transmissibility (7–9).

Despite the unprecedented, rapid development of COVID-19 vaccines, only ~63% of the global population are fully vaccinated (as of 14th March 2022) (6). Hence, there is still a need for COVID-19 vaccines that can be produced locally in low- and middle-income countries (LMICs), where the vaccination rates are the lowest worldwide (6). In previous work, we developed a vaccine candidate named NDV-HXP-S (10) that can be manufactured like influenza virus vaccines at low cost in embryonated chicken eggs in facilities located globally (11). This vaccine is based on an avirulent Newcastle disease virus (NDV) strain that presents a SARS-CoV-2 spike protein stabilized in its prefusion-conformation by the introduction of six proline mutations (HexaPro, HXP-S) (4, 12) and elimination of the furin cleavage site. NDV-HXP-S can be used as live vaccine (11, 13, 14) or as an inactivated vaccine (11, 15). Clinical trials with a live version are ongoing in Mexico (NCT04871737) and the United States (NCT05181709), while the inactivated vaccine is being tested in Vietnam (NCT04830800), Thailand (NCT04764422),...
and Brazil (NCT04993209). Interim results from the initial Phase I/II trials have demonstrated that the vaccine is safe and immunogenic (15–17).

Here, we present the development of NDV-HXP-S variant vaccines displaying the VOC spike proteins of Beta, Gamma, and Delta (Fig. 1B). We tested the immunogenicity and protection induced by vaccination with inactivated NDV-HXP-S variants in mice. We observed that variant-specific vaccines induced the strongest antibody responses toward the homologous SARS-CoV-2 VOC. Furthermore, we found that a combination of multivalent NDV-HXP-S with the ancestral, Beta, and Delta provided a broader protection against a panel of VOC than the monovalent formulations.

RESULTS

Design and production of NDV-HXP-S variant vaccines. NDV-HXP-S variant vaccines based on three VOC, Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), were rescued using reverse genetics in mammalian cell cultures and further amplified in specific-pathogen free (SPF) embryonated chicken eggs as previously described (Fig. 2) (11). The nucleotide sequence of the constructs was codon-optimized for mammalian host expression. The HXP-S sequence was inserted between the P and M genes of the NDV genome. We removed the polybasic cleavage site (682RRAR685) and replaced the transmembrane domain (TM) and cytoplasmic tail (CT) of the spike with those from the fusion (F) protein of La Sota NDV. The HXP mutations were introduced into the spike S2 region of all three variant S proteins to improve their stability as reported previously (Fig. 2A and B) (12). In addition, we found that a completely cleaved Delta spike was observed when the Delta specific S-P681R mutation was included. Therefore, we kept the 681 as proline to ensure the homogeneity of the prefusion spike protein (S0) (Fig. 2C).

Research-grade beta-propiolactone (BPL) inactivated NDV-HXP-S variant vaccine preparations were produced as described previously (11, 18). Harvested allantoic fluid was inactivated with 0.05% BPL for 30 min at 4°C, and later the remaining BPL was heat inactivated at 37°C for 2 h in continuous shaking. Virus was further purified and concentrated from allantoic fluid after inactivation through a sucrose cushion and resolved on a sodium dodecyl–sulfate polyacrylamide gel (SDS–PAGE) with Coomassie blue staining to evaluate the presence of all NDV-HXP-S proteins. NDV-HXP-S variants showed an extra band between 160 kDa and 260 kDa below the L protein of the NDV that corresponds to the size of the uncleaved spike (S0, Fig. 2D) (11). Of note, NDV-HXP-S Delta virus presents a higher ratio of spike (S0) over HN band compared to the ancestral Wuhan construct, which did not impair the virus growth to high titers.

NDV-HXP-S variant vaccines protect against homologous challenge in mouse models. The immunogenicity and in vivo protection of the new NDV-HXP-S Beta and Gamma vaccine candidates was first evaluated in BALB/c mice transduced with a nonreplicating human adenovirus 5 expressing human angiotensin-converting enzyme 2 (Ad5-hACE2) (Fig. 3A). A two-dose intramuscular (IM) vaccination regimen with a total protein content of 1 μg per mouse of purified NDV-HXP-S vaccine candidate with a 3-week period between doses was followed. Three weeks after the boost, mice were transduced by intranasal (IN) administration of the Ad5-hACE2, and 5 days later mice were challenged with SARS-CoV-2 viruses via the IN route, as previously described (19). Two days after the challenge, viral titers in the lung homogenates were quantified by plaque assays. Vaccination with wild-type NDV was used as negative control (Fig. 3B).

A viral titer reduction of 2,237-fold, 2,015-fold, and 285-fold was obtained in the homologous challenge using monovalent vaccination regimens with the ancestral Wuhan, Beta, and Gamma NDV-HXP-S vaccines compared to the negative control, respectively (P value < 0.05 versus the negative control, Fig. 3C). Heterologous protection with original NDV-HXP-S against Beta and Gamma challenge was observed with a viral titer reduction of 330-fold and 139-fold compared to the negative control, respectively, in agreement with previous studies (11), although a high heterogeneity was observed in the ancestral group against Beta. Beta NDV-HXP-S vaccine showed cross-protection against the Gamma variant challenge, and vice versa. However, an asymmetric weaker protection of Beta and Gamma vaccines was observed against the WA1 challenge.
Design, production, and characterization of NDV-HXP-S variant vaccines. (A) Structure and design of the NDV-HXP-S construct. The different SARS-CoV-2 spike sequences were introduced between the P and M genes of LaSota L289A NDV strain. The ectodomain of the spike was connected to the transmembrane domain and cytoplasmic tail (TM/CT) of the F protein of the NDV. The original polybasic cleavage site was removed by mutating RRAR to A. The HexaPro (F817P, A892P, A899P, A942P, K986P, and V987P) stabilizing mutations were introduced. The sequence was codon-optimized for mammalian host expression. Ancestral Wuhan HXP-S sequence is aligned with the new variant constructs: Beta, Gamma, and Delta. Changes in the N-terminal domain (NTD), the Receptor Binding Domain (RBD), and in the Spike 2 (S2) with respect to the original HXP-S sequence are highlighted in red, pink, and light purple, respectively. (B) NDV-HXP-S variants were rescued by reverse genetics as previously described (25). Cells were cotransfected with the expression plasmid required for replication and transcription of the NDV viral genome (NP, P, and L), together with the full length NDV cDNA. One day later, transfected cells were co-cultured with DF-1 cells. After 2 or 3 days, the tissue culture supernatants were inoculated into 8- or 9-day-old specific pathogen free (SPF) embryonated chicken eggs. Antigen identity was confirmed by biochemical methods and sequencing. The genetic stability of the recombinant viruses was evaluated across multiples passages on 10-day-old-SPF embryonated chicken eggs. NDV-HXP-S vaccine was inactivated with BPL and purified by sucrose cushion ultracentrifugation. (C) Comparison of NDV-HXP-S Delta virus versus NDV-HXP-S Delta with P681R mutation. The spike protein and NDV HN proteins were detected by Western blot using an anti-spike 2B3E5 mouse monoclonal antibody and an anti-HN 8H2 mouse monoclonal antibody, respectively. (D) Protein staining of NDV-HXP-S variant vaccines resolved on 4–20% SDS-PAGE. The viral proteins were visualized by Coomassie blue staining (L, S0, HN, N, P, and M). The uncleaved S0 spike protein is highlighted in blue with an approximate size of 200 kDa.
Together with the in vivo challenge study, mice were bled 3 weeks after boost to measure the spike-specific IgG levels. Antibody titers after vaccination against Wuhan, Beta, and Gamma spikes are compared in Fig. 3D to F, respectively. Wuhan spike-specific IgG serum antibody titers were higher after the vaccination, with the original construct compared to Beta and Gamma NDV-HXP-S vaccinations (Fig. 3D). Similar Beta and Gamma spike-specific antibody titers were obtained with all three vaccination regimens (Fig. 3E and F). These results correlate with the challenge against the three viruses, where a similar cross-protection was obtained against Beta and Gamma challenges with all three vaccination regimens, although the higher heterogeneity was observed in the in vivo challenge.
study for some groups. As the Delta variant emerged, we also measured post-boost serum antibodies against the Delta spike (Fig. 3G). Compared to the other spike-specific titers, the levels of cross-reactive antibodies against the Delta spike were reduced in all three vaccination groups, suggesting a higher drop in protection against this variant with the current constructs tested.

Trivalent and tetravalent NDV-HXP-S variant vaccinations increase protection in vivo against phylogenetically distant SARS-CoV-2 variants. Following the characterizations of Beta and Gamma NDV-HXP-S vaccines, the Delta VOC appeared in India and rapidly replaced the other variants (Fig. 1B). When the Delta vaccine construct was generated, a second mouse immunization and challenge study was performed testing vaccine formulations containing the Delta component (Fig. 4A). Based on the previous results, the following groups were evaluated: monovalent ancestral, monovalent Delta, bivalent Ancestral and Delta, sequential vaccination with a first dose of Ancestral followed by Delta, trivalent (Ancestral, Delta, and Beta), and tetravalent

![Diagram](Trivalent and tetravalent NDV-HXP-S vaccination regimens induce protection against phylogenetically distant SARS-CoV-2 variants. A and B) Design of the study and groups. Eight- to 10-week-old female BALB/c mice were used either vaccinated with 1 μg of total dose of inactivated NDV-HXP-S variant vaccines or WT NDV (negative control). Two immunizations were performed via the intramuscular (IM) route at D0 and D21. At D49, mice were treated with AdS-hACE2. At D49, mice were challenged with Wuhan-like (USA-WA1/2020), Delta (B.1.617.2), or Mu (B.1.621) strains and at day two after challenge, lungs were harvested and homogenized in 1 mL PBS and titers were measured by plaque assay. (C) Viral titers after challenge (n = 5). Viral titers were measured by plaque assay on Vero E6 cells for USA-WA1/2020 challenge and Vero-TMPRSS2 cells for Delta and Mu challenges and plotted as GMT of PFU/mL (limit of detection equals to 50 PFU/mL; a titer of 25 PFU/mL was assigned to negative samples). The error bars represent geometric standard deviation. Statistical differences were analyzed by ordinary one-way ANOVA corrected for Dunnett’s multiple-comparison test. The P values and geometric mean fold titers over the control are indicated in blue and gray, respectively. (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). (D) Panel of neutralizing activity. Postboost pooled sera were tested in microneutralization (MNT) assays against USA-WA/2020 strain, Delta (B.1.617.2) variant, Beta (B.1.351) variant, and Omicron (B.1.1.529) variant in technical duplicates. GMT serum dilutions inhibiting 50% of the infection (ID50) were plotted (limit of detection equals to 10 and was assigned to negative samples). Geometric mean fold change is added in blue.
(Ancestral, Delta, Beta, and Gamma). In all cases, the vaccination dose was 1 μg of total protein (Fig. 4B).

In this study, we wanted to test not only the protection against homologous challenge, but also against a phylogenetically distant SARS-CoV-2 variant that is unmatched to any vaccine component. To do so, animals in each group were divided into 3 subgroups and challenged with WA1, Delta, and Mu variants (Fig. 4C). As expected, Ancestral and Delta showed protection against its homologous virus challenge. Of note, bivalent, trivalent, and tetravalent vaccines showed comparable levels of protection as the homologous monovalent vaccines against WA1 (Wuhan-like) and Delta challenges. Viral titers were reduced in the trivalent condition 21,845-fold and 3,119-fold compared to the negative control in WA1 and Delta challenges, respectively. However, a sequential vaccination regimen was shown to be less protective, with only a 54-fold mean titer reduction and a higher heterogeneity in the Delta challenge, where only two out of five mice seemed to be protected. In the case of the Mu challenge, trivalent formulation was proven to be the best with a titer reduction of 594-fold (Fig. 4C; P value, 0.0001 compared to the negative control). This reduction was 2.4 times higher than any of the other vaccination strategies tested, including that of the tetravalent preparation, where two out of five showed viral titers higher than 10^3 PFU/mL (for discussion see below).

Considering the urgency of testing the Omicron variant, which were newly emerged and quickly spread, we decided to compare the neutralizing activity of post-boost serum antibodies against the Wuhan, Delta, Beta, and Omicron variants in authentic virus neutralization assays (Fig. 4D). A similar 50% inhibitory dilution (ID50) was obtained against Wuhan in all vaccinated groups except for Delta (0.4-fold compared to the ancestral group). In the case of Delta microneutralization, the neutralizing activity was increased in the trivalent and tetravalent (2.0-fold and 2.5-fold compared to the ancestral strain, respectively), whereas the original NDV-HXP-S alone and sequential showed a weaker neutralizing activity. A similar ID50 was obtained against Beta with monovalent, bivalent, and sequential strategies, whereas it was increased 2.5-fold and 2.7-fold in the trivalent and tetravalent groups, respectively. Little neutralizing activity was found against Omicron in the ancestral vaccination, whereas the Delta vaccine showed a 5.6-fold increase compared to the vaccination with the monovalent ancestral NDV-HXP-S. The neutralization titer against the Omicron was further increased by the trivalent and tetravalent vaccines (9.3-fold and 11.0-fold compared to the monovalent ancestral NDV-HXP-S vaccine group, respectively).

**Trivalent and tetravalent NDV-HXP-S vaccinations increase antibody titers to the spike of SARS-CoV-2 variants.** In the attempt to elucidate the mechanism of cross-protection induced by the multivalent vaccine formulations, antibody-binding profiles were measured against a panel of SARS-CoV-2 spike proteins, including the Wuhan, Delta, Alpha, Beta, Gamma, and Omicron (Fig. 5A and B). Wuhan and Delta spike-specific IgG levels were comparable among all vaccination groups. In the case of Beta, increases of 2.9-fold and 1.9-fold were observed in the trivalent and tetravalent vaccinations compared to the monovalent ancestral group, respectively. An increase was also observed against Alpha (1.7-fold) and Gamma spikes (1.5-fold) in the trivalent condition (Fig. 5A). Finally, vaccinated mice sera were also tested against an Omicron spike. Omicron presents almost 40 different amino acid changes and deletions. A general reduction in antibody titers against Omicron spike was found in all groups compared to the other spikes tested (Fig. 5A, see y axes). Despite this drop, the addition of Delta and Beta increased spike-specific IgG titers against Omicron: 2.4-fold in the Delta vaccinated group, 5.7-fold with trivalent, and 3.0 times with the tetravalent vaccinated group compared to the monovalent ancestral vaccinated group, which correlates with the neutralization titers against Omicron (Fig. 4D). Overall, the trivalent immunization regimen induced the highest titers of spike-specific antibody levels across all the variants tested (Fig. 5B).

**DISCUSSION**

The COVID-19 pandemic has seen an unprecedented race in the development of next generation vaccines. Compared to the traditionally slow vaccine development, novel vaccine platforms such as Moderna and Pfizer/BioNTech's mRNA vaccines or Janssen and
AstraZeneca’s adenovirus-based vaccines have been authorized for emergency use in 1 year (6, 20). Despite this tremendous effort, only ~63% of the global population has been fully vaccinated, largely due to unequal vaccine distribution (as of March 14, 2022) (6). This fact, together with the continuing emergence of VOC, which present a higher transmissibility and resistance to vaccine-mediated protection, has caused thousands of deaths per day since the beginning of the pandemic. In the last few months, the situation has worsened with the arrival of Omicron, where the world has experienced the highest number of daily cases to date (6).

With the NDV-based vaccine platform, we successfully constructed variant-specific vaccines for Beta, Gamma, and Delta variants. In mice, variant-specific vaccines effectively conferred protection against homologous viruses. To test if the co-administration of prior variants could potentially induce cross-protective immune responses against unmatched and antigenically distinct lineages, we examined bivalent, sequential, trivalent, and tetravalent formulations of inactivated NDV-HXP-S variant vaccines. Bivalent vaccination with the ancestral and Delta showed an improved immunogenicity compared to the monovalent vaccinations, whereas the sequential strategy, where the same ancestral and Delta candidates were given in consecutive doses, showed no improvement compared to the monovalent ancestral Wuhan NDV-HXP-S group. Comparable levels of protection by a sequential administration of variant-like vaccines versus a booster dose of the original vaccine candidate have been observed in other
preclinical studies (21, 22); however, the long-term benefits of these heterologous boosters are still to be investigated.

Trivalent and tetravalent formulations presented synergistic responses in terms of the protection against the unmatched Mu VOC in challenge studies in mice (Fig. 4C). Similarly, in vitro microneutralization assays have also demonstrated an increase in cross-neutralizing antibodies against all viruses tested, including the Omicron variant (Fig. 4D). Phylogenetically, Wuhan, Beta, Gamma, and Delta are distinct from each other. A multivalent vaccination may induce several repertoires of cross-neutralizing antibodies that might target some common epitopes with other unmatched variants. There are several explanations for this phenomenon. One possibility is that each variant contributes with unique neutralizing epitope(s) that expand the repertoire of neutralization responses. It is also possible that conserved neutralizing epitopes shared by all the variants are more immunodominant in one variant than the other due to conformational changes resulting from spike mutations. Therefore, one variant may have induced more cross-neutralizing antibodies than the other. When trivalent and tetravalent vaccination regimens are compared with each other, no advantage of the tetravalent regimen compared to trivalent was observed in the in vivo challenge experiment in mice. The dose reduction from 0.33 μg to 0.25 μg per variant or the lower immunogenicity of the Gamma vaccine might explain these results. This study presented some limitations, due to the lack of Mu neutralization assay set up at that time and much attenuated pathogenicity of Omicron in existing animal models (23). Future studies will be performed in the hamster model with more SARS-CoV-2 induced disease readouts to address these limitations. The studies presented here follow a two-dose regimen. A third dose of NDV-HXP-S or a booster dose of NDV-HXP-S after two immunizations with other types of vaccines will also be of interest in future studies.

The NDV-HXP-S vaccine has proven its safety and immunogenicity in several preclinical and clinical studies. As an egg-based vaccine, NDV-HXP-S could be produced using the egg-based influenza virus vaccine manufacturing capacities located worldwide. Sparrow and colleagues estimated that influenza virus vaccine manufacturing capacities on their own can produce billions of doses annually (10). Here, vaccination with a trivalent formulation in mice was performed by maintaining the total dose of the monovalent vaccine (1 μg of total protein). Hence, the manufacturing capabilities required to produce this new formulation will remain the same.

In summary, we present the development of novel NDV-HXP-S variant vaccines and test their combination in a trivalent formulation to extend the generation of neutralizing antibodies against unmatched VOCs. This formulation exceeds the breadth of protection of the other formulations we have tested so far. This is of special interest because Omicron (B.1.1.529 or BA.1) has quickly diverged into different sublineages (BA.1.1, BA.1, BA.2.12.1, BA.3, BA.4 and BA.5) and has gained prevalence globally (www.nextstrain.org/ncov). A variant-specific vaccine of any platform comes with an intrinsic disadvantage. It can only be used after the new vaccine candidate is produced and authorized by the health authorities. We believe that a more thorough selection and testing of several variant vaccines in multivalent formulations might be an effective strategy for vaccination against future SARS-CoV-2 variants.

MATERIALS AND METHODS

Cells. DF-1, (ATCC CRL-12203), BSRT7 (24), and VERO-E6 (ATCC, CRL-1586) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, MA, USA) containing 10% (vol/vol) fetal bovine serum (FBS), 100 unit/mL of penicillin, 100 μg/mL of streptomycin (P/S; Gibco), and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at 37°C with 5% CO2. VERO-TMPRSS2 cells (BPS Biosciences, #79081) were maintained in DMEM (Gibco) containing 10% (vol/vol) FBS, 100 unit/mL of penicillin, 100 μg/mL of streptomycin (P/S; Gibco), 5 mL of Nonessential Amino Acid Solution (NEAA, Corning MEM, NY, USA), 3 μg/mL puromycin (Inviogen, CA, USA) and 0.1 mg/mL Normocin (Inviogen) at 37°C with 5% CO2.

Plasmids. Spike variant mutations were introduced into the HXP-S sequence in silico, and the new constructs were obtained as synthetic double-stranded DNA fragments from Integrated DNA Technologies, using the gBlocks Gene Fragments service and PCR (11). Briefly, the variant HXP-S were inserted into the pNDV_LS/L289A rescue plasmid (between P and M genes) by In-Fusion Cloning (Clontech, CA, USA). The recombinant product was transformed into MAX Efficiency Stbl2 Competent Cells (Thermo Fisher Scientific,
MA, USA) to generate the pNDV/HXP-S rescue plasmid. The plasmid was purified using PureLink HiPure Plasmid Maxiprep Kit (Thermo Fisher Scientific).

**Rescue of the NDV-HXP-S.** As described in our previous studies (18), BSR77 cells stably expressing the T7 polymerase were seeded onto 6-well plates at 3 × 10⁶ cells per well in duplicate. The next day, cells were transfected with 2 μg of pNDV-HXP-S, 1 μg of pTM1-NP, 0.5 μg of pTM1-P, 0.5 μg of pTM1-L, and 1 μg of pC7-T7opt and were re-suspended in 250 μL of a modified Eagle’s Minimum Essential Medium (Opti-MEM; Gibco). The plasmid cocktail was then gently mixed with 15 μL of TransIT LT1 transfection reagent (Virus, GA, USA). The growth medium was replaced with Opti-MEM during transfection. To increase rescue efficiency, BSR77-D1 cells were washed with warm PBS and trypsinized. Trypsinized cells were neutralized with an excessive amount of growth medium. BSR77 cells were mixed with DF-1 cells (~1: 2.5) in a 10-cm dish. The cocultures were incubated at 37°C overnight. The next day, the medium was removed, and cells were gently washed with warm PBS, Opti-MEM supplemented with 1% FBS, and 0.1 μg/mL of tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin was added. The cocultures were incubated for 2 or 3 days before infection into 8- or 9-day-old specific pathogen free (SPF) embryonated chicken eggs (Charles River Laboratories, CT, USA). To inoculate eggs, cells and supernatants were harvested and homogenized by several syringe strokes. One or two hundred μL of the mixture was injected into each egg. Eggs were incubated at 37°C for 3–5 days and cooled at 4°C overnight. Allantoic fluids (AF) were harvested from cooled eggs, and the rescue of the viruses was determined by hemagglutination (HA) assays. RNA of the rescued virus was extracted, and RT-PCR was performed to amplify the cDNA segments of the viral genome. The cDNA segments were then sequenced by Sanger sequencing (Pisomagen, MA, USA). The genetic stability of the recombinant viruses was evaluated across multiple passages in 10-day-old SPF embryonated chicken eggs.

**Virus titration by EID₅₀ assays.** Fifty percent of (embryonated) egg infectious dose (EID₅₀) assay was performed in 9- to 11-day old chicken embryonated eggs. Virus in allantoic fluid was 10-fold serially diluted in PBS, resulting in 10⁻¹ to 10⁻¹⁰ dilutions of the virus. One hundred μL of each dilution was injected into each egg for a total of 5–10 eggs per dilution. The eggs were incubated at 37°C for 3–4 days and then cooled at 4°C overnight, and allantoic fluids were collected and analyzed by HA assay. The EID₅₀ titer of the NDV, determined by the number of HA-positive and HA-negative eggs in each dilution, was calculated using the Reed and Muench method.

**Preparation of inactivated concentrated virus.** The viruses in the allantoic fluid were first inactivated using 0.05% beta-propiolactone (BPL) as described previously (18). To concentrate the viruses, allantoic fluids were clarified by centrifugation at 4,000 rpm at 4°C for 30 min using a Sorvall Legend RT Plus Refrigerated Benchtop Centrifuge (Thermo Fisher Scientific). Clarified allantoic fluids were loaded on top of a 20% sucrose cushion (in PBS, sucrose). Ultracentrifugation in a Beckman L7-65 ultracentrifuge at 25,000 rpm for 2 h at 4°C using a Beckman SW28 rotor (Beckman Coulter, CA, USA) was performed to pellet the viruses through the sucrose cushion while soluble egg proteins were removed. The virus pellets were re-suspended in PBS (pH 7.4). The total protein content was determined using the bicinchoninic acid (BCA) assay (Thermo Fisher Scientific).

**SDS-PAGE and Western blot.** The concentrated NDV-HXP-S or WT NDV was mixed with Novex Tris-Glycine SDS Sample Buffer (2×) (Thermo Fisher Scientific), NuPAGE Sample Reducing Agent (10×) (Thermo Fisher Scientific), and PBS at appropriate amounts to reach a total protein content. The mixture was heated at 90°C for 5 min. The samples were mixed by pipetting and loaded to a 4–20% 10-well Mini-Protein TGX gel precast gel. Ten μL of the Novex Sharp Pre-Stained Protein standard (Thermo Fisher Scientific) was used as the ladder. The electrophoresis was run in Tris/Glycine SDS/Buffer (2×) for a minimum of 1 h to overnight. The SimplyBlue SafeStain was decanted and the gel was washed with distilled water several times until the dye from in the gel was no longer visible. The gel was stained with 20 mL of SimplyBlue SafeStain (Thermo Fisher Scientific) for a minimum of 1 h to overnight. The SimplyBlue SafeStain was decanted and the gel was washed with distilled water several times until the background was clear. Gels were imaged using the Bio-Rad Universal Hood III Molecular imager (Bio-Rad) and processed by Image Lab Software (Bio-Rad).

For Western Blot, proteins were transferred onto polyvinylidene difluoride (PVDF) membrane (GE Healthcare, IL, USA). The membrane was blocked with 5% dry milk in PBS containing 0.1% vol/vol Tween 20 (PBST) for 1 h at RT. The membrane was washed with PBST on a shaker 3 times (10 min at RT each time) and incubated with primary antibodies diluted in PBST containing 1% bovine serum albumin (BSA) overnight at 4°C. To detect the spike protein of SARS-CoV-2, a mouse monoclonal antibody 2B3ES recognizing the S1 kindly provided by Thomas Moran at ISMMS was used. The HN protein was detected by mouse monoclonal antibody 8H2 (MCA2822, Bio-Rad). The membranes were then washed with PBST in a shaker 3 times (10 min at RT each time) and incubated with sheep anti-mouse IgG linked with horse-radish peroxidase (HRP) diluted (1:2,000) in PBST containing 5% dry milk for 1 h at RT. The secondary antibody was discarded and the membranes were washed with PBST in a shaker 3 times (10 min at RT each time). Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) was added to the membrane, and the blots were imaged using the Bio-Rad Universal Hood II Molecular imager (Bio-Rad) and processed by Image Lab Software (Bio-Rad).

**Animal experiments.** All the animal experiments were performed in accordance with protocols approved by the Icahn School of Medicine at Mount Sinai (SMMS) Institutional Animal Care and Use Committee (IACUC). All experiments with live SARS-CoV-2 were performed in the Centers for Disease Control and Prevention (CDC)/U.S. Department of Agriculture (USDA)-approved biosafety level 3 (BSL-3) biosafety facility of the Global Health and Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai, in accordance with institutional biosafety requirements.

**Mouse immunization and challenge studies.** Female BALB/c mice were used in all studies. Intramuscular vaccination using 1 μg of total protein of inactivated NDV-HXP-S vaccine or negative control WT
NDV was prepared in 100 μL total volume. Two immunizations were performed for all the mice with a 21-day interval. For SARS-CoV-2 infection, mice were intranasally infected with 2.5 × 10⁶ PFU of Ad5-hACE2 5 days prior to being challenged with 1 × 10⁷ PFU USA-WA1/2020 strain (Wuhan-like). 3.4 × 10⁷ PFU of the hCoV-19/USA-MD-HP01542/2021 JHU strain (Beta, kindly provided by Andrew Pekosz from Johns Hopkins Bloomberg School of Public Health), 6.3 × 10⁶ PFU of the hCoV-19/Japan/TY7-503/2021 strain (Gamma), 1.6 × 10⁶ PFU of the hCoV-19/USA-NYMSHSPSP-PV299955/2021/2021 strain (Delta, obtained from Viviana Simon, Mount Sinai Pathogen Surveillance program), and 5.0 × 10⁶ PFU of the hCoV-19/USA/WI-UW-4340/2021 strain (Mu, kindly provided by Michael S. Diamond from Washington University Medical School in St. Louis). Viral titers in the lung homogenates of mice 2 days postinfection were used as the readout for protection. Briefly, the lung lobes were harvested from a subset of animals per group and homogenized in 1 mL of sterile PBS. Viral titers in the lung homogenates were measured by plaque assay on vero-E6 or Vero-TMPRSS2 cells. Blood was collected by submandibular vein bleeding. Sera were isolated by low-speed centrifugation and stored at −80°C before use.

**Microneutralization assays using the authentic SARS-CoV-2 viruses.** Microneutralization assays using the authentic SARS-CoV-2 viruses were performed as described previously in Vero-TMPRSS2 (5). All procedures were performed in a BSL-3 facility at the Icahn School of Medicine at Mount Sinai following standard safety guidelines. 100 μL of hCoV-19/USA/WA1/2020 strain was added to 10,000 well permeabilized by adding 150 μL of the corresponding antibody dilutions plus 100 μL of the Receptor Binding Domain (RBD)-specific monoclonal antibody CR3022 (28). Recombinant Gamma (10795-CV-100) and Delta (10878-CV-100) spike proteins were purchased from R&D Systems (R&D Systems, Bio-Techne, MN, USA).

**Spike-specific IgG in mice sera vaccinated with NDV-HXP-5 was measured by ELISA as described previously (18, 29).** Proteins were coated onto Immulon 4 HBX 96-well microtiter plates (Thermo Fisher Scientific) at 2 μg/mL in 1× coating buffer (SeraCare Life Sciences Inc., MA, USA) at 50 μL/well overnight at 4°C. All plates were washed 3 times with 225 μL PBS containing 0.1% (vol/vol) Tween 20 (PBST) and 220 μL blocking solution (3% goat serum, 0.5% nonfat dried milk powder, 96.5% PBST) was added to each well and incubated for 1 h at RT. Individual serum samples or pooled sera were serially diluted 3-fold in blocking solution followed by a 1-h incubation at RT. Plates were then washed 3 times with PBST and 50 μL of mouse IgG-horseradish peroxidase (HRP) conjugated antibody (Cytiva, GE Healthcare) was added at a dilution of 1:3,000 in blocking solution. After 1 h, plates were washed 3 times with PBST and developed using SigmaFast OPD (Sigma-Aldrich, MO, USA) for 10 min. Reactions were stopped by adding 50 μL 3M hydrochloric acid, and absorbance at 492 nm was determined on a Synergy 4 plate reader (BioTek, Agilent Technologies Inc., CA, USA) or similar. For each ELISA plate, the blank average absorbance plus 3 standard deviations was used as a cutoff to determine endpoint titers and the area under the curve (AUC) using GraphPad Prism.
performed to calculate the 50% inhibitory dilution (ID50), with top and bottom constraints set to 100% and 0% respectively. All samples were analyzed in a blinded manner.

**SARS-CoV-2 plaque assay.** Plaque assays with SARS-CoV-2 viruses were performed in the BSL3 facility. Vero-E6 cells or Vero-TMPRSS2 were seeded onto 12-well plates in growth media at 1.5 and cultured for 2 days. Tissue homogenates were 10-fold serially diluted in infection medium (DMEM containing 2% FBS, 100 unit/mL of penicillin, 100 μg/mL of streptomycin [P/S; Gibco], and 10 mM HEPES). Two hundred μL of each dilution was inoculated onto each well starting with a 1:10 dilution of the sample. The plates were incubated at 37°C for 1 h with occasional rocking every 10 min. The inoculum in each well was then removed and 1 mL of agar overlay containing 0.7% of agar in 2× MEM was placed onto each well. Once the agar was solidified, the plates were incubated at 37°C with 5% CO2. Two days later, the plates were fixed with 5% formaldehyde in PBS overnight before being taken out from BSL3 for subsequent staining under BSL2 conditions. The plaques were immunostained with an anti-SARS-CoV-2 NP primary mouse monoclonal antibody, 1C7C7, kindly provided by Thomas Moran at ISMMS. An HRP-conjugated goat anti-mouse secondary antibody was used at 1:2,000, and the plaques were visualized using TrueBlue Peroxidase Substrate (SeraCare Life Sciences Inc).

**Phylogenetic tree.** The phylogenetic tree was built from 3057 SARS-CoV-2 genome samples between December 2019 and February 2022. Phylogenetic tree and frequency timelines were obtained from the Nextstrain/ncov Project within the GISAID initiative (www.nextstrain.org/ncov) under CC-BY (30, 31).

**Statistics.** A one-way ANOVA with Dunnet multiple-comparison test was used to compare the plaque assay and ELISA biding titters. Statistical analyses were performed using Prism software (GraphPad).

**Ethics statement.** All animal procedures in this study were performed in accordance with the animal protocol that was reviewed and approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC).

**Data availability.** Data is available upon request.

**ACKNOWLEDGMENTS**

We thank Benhur Lee for kindly sharing the BSRT7 cells, Thomas Moran for the 1C7C7 antibody, and Prajakta Warang for the VERO-TMPRSS2 cell culture. We thank Randy Albrecht for support with the BSL-3 facility, procedures, and management of import/export at the Icahn School of Medicine at Mount Sinai, New York. This work was partially supported by the NIAID-funded Center of Excellence for Influenza Research and Surveillance (CEIRS, HHSN272201400008C, P.P.) and Center of Excellence for Influenza Research and Response (CEIRR), 75N93021C00014, A.G.-S., NIH grant R01 DK130425/DK/NIDDK (M.S.), NIAID R21AI157606 (L.C.), and a grant from an anonymous philanthropist to Mount Sinai (P.P., F.K., A.G.-S.).

The Icahn School of Medicine at Mount Sinai has filed patent applications titled “Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein and Uses Thereof” that names P.P., F.K., A.G.-S., and W.S. as inventors. The A.G.-S laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamamar, ImmunityBio, Accurius, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Merck, and Nanocomposix, and A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalta, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamamar, Paratus, CureLab Oncology, CureLab Veterinary, Synairgen, and Pfizer. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503, and 63/024,436) that list F.K. as coinventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. All other authors declare no competing interests.

Conceptualization and design: I.G.-D., W.S., P.P.; NDV rescue and characterization: J.L.M., S.S., N.L.; vaccine preparation and animal experiments; I.G.-D., Y.L., W.S.; serology: I.G.-D., T.Y.L., S.M.; protein and virus reagents; G.S., G.S., M.S., I.M., L.C., A.G.-S.; microneutralization assay: J.M.C., F.K.; data analysis: I.G.-D., W.S., P.P.; first draft: I.G.-D., W.S., P.P.; manuscript was reviewed and approved by all authors.

**REFERENCES**

1. Carreno JM, Al shammary H, Singh G, Raskin A, Amanat F, Amoako A, Gonzalez-Reiche AS, van de Guchte A, Study Group P, Srivastava K, Sordillo EM, Sather DN, van Bakel H, Krammer F, Simon V. 2021. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. EBioMedicine 73: 103626. https://doi.org/10.1016/j.ebiom.2021.103626.
13. Tcheou J, Raskin A, Singh G, Kawabata H, Bielak D, Sun W, González-Morales J, Lozano-Dubernard B. 2022. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1 trial. E Clinical Medicine 45:101323. https://doi.org/10.1016/j.eclinm.2021.101323.

16. Ponce-de-León STMM, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz-De la Rosa G, Viguera-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Dominguez I, Luis Martínez-Guevara J, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. 2022. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: interim results of a non-randomized open label phase I trial in Mexico. medRxiv. https://doi.org/10.1101/2022.02.08.22270676.

14. Carreño JM, Alshammary H, Tcheou J, Singh G, Rashid AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak GA, Gonzalez-Reiche AS, Dambrauskas N, Vidovich V, Alburquerque B, Amaoko AA, Banu R, Beach KE, Bermúdez-González MC, Cai YG, Ceglia I, Cognigni C, Farrugia K, Gleason CR, van de Guchte A, Kleiner G, Khullar Z, Lyttle N, Mendez WA, Mulder LCO, Oostenrijk J, Roeker A, Rollinger AT, Sakena M, Panic-Mondolfi AE, Polanco J, Sivastava K, Sideris DN, Bajic G, van Bakel H, Simon V, Krammer F. 2022. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602:E682–688. https://doi.org/10.1038/s41586-021-03846-z.

10. Sparrow E, Wood JG, Chadwick C, Newall AT, Torvaldsen S, Moen A, Torelli G. 2022. Omicron and S-gene target failure. Oxidative Med Cell Longev 2021:1505. https://doi.org/10.1155/2021/1505.

8. Li A, Maier A, Carter M, Guan TH. 2022. Omicron and S-gene target failure. Emerging Microbes Infect 9:2433. https://doi.org/10.1038/s41608-022-03972-3.

7. Mahase E. 2022. Omicron sub-lineage BA.2 may have “substantial growth advantage.” UKHSA reports. BMJ 376:o263. https://doi.org/10.1136/bmj.o263.

6. Ritchie H, Mathieu E, Rodés-Guirao L, Ortiz-Ospina E, Krammer F. 2022. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602:E682–688. https://doi.org/10.1038/s41586-021-03846-z.

5. Carreño JM, Alshammary H, Tcheou J, Singh G, Rashid AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak GA, Gonzalez-Reiche AS, Dambrauskas N, Vidovich V, Alburquerque B, Amaoko AA, Banu R, Beach KE, Bermúdez-González MC, Cai YG, Ceglia I, Cognigni C, Farrugia K, Gleason CR, van de Guchte A, Kleiner G, Khullar Z, Lyttle N, Mendez WA, Mulder LCO, Oostenrijk J, Roeker A, Rollinger AT, Sakena M, Panic-Mondolfi AE, Polanco J, Sivastava K, Sideris DN, Bajic G, van Bakel H, Simon V, Krammer F. 2022. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602:E682–688. https://doi.org/10.1038/s41586-021-03846-z.

4. Holder J. Tracking coronavirus vaccination around the world. 2022. New York Times, New York, NY. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Accessed 5 February, 2022.
27. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. 2020. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol 57:e100.

28. ter Meulen J, van den Brink EN, Poon LLM, Marissen WE, Leung CSW, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruij J, Peiris JSM, Goudsmit J. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3:e237. https://doi.org/10.1371/journal.pmed.0030237.

29. Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, Amanat F, Schäfer A, Dinning KH, García-Sastre A, Krammer F, Baric RS, Palese P. 2020. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 62:103132. https://doi.org/10.1016/j.ebiom.2020.103132.

30. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34:4121–4123. https://doi.org/10.1093/bioinformatics/bty407.

31. Sagulenko P, Puller V, Neher RA. 2018. TreeTime: maximum-likelihood phylodynamic analysis. Virus Evol 4:vex042.